Epic Sciences

Epic Sciences Overview

Founded 2008
Founded
Status Private
Employees 70
Employees
Latest Deal Type Series E
Latest Deal Amount $52M
Latest Deal Amount
Investors 20

Epic Sciences General Information

Description

Developer of diagnostic tests technology intended to help the rapid and non-invasive detection of genetic and molecular changes in cancer throughout. The company's technology not only assesses the number of circulating tumour cells and its subtypes but also profiles single-cell phenotype and genotype as well as provide near real-time information about each different cellular population before, during and after treatments-with no cell left behind, enabling oncologists to identify and analyze rare disease cells from a tube of blood that also contains millions of normal cells.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Diagnostic Equipment
Primary Office
  • 9381 Judicial Drive
  • Suite 200
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000

Epic Sciences Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Epic Sciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC (Series E) 12-Sep-2018 $52M 00000 00000 Completed Generating Revenue
10. Debt - General 01-Aug-2017 0000 00000 Completed Clinical Trials - General
9. Later Stage VC (Series D) 28-Apr-2017 0000 0000 0000 Completed Clinical Trials - General
8. Later Stage VC (Series C1) 23-May-2016 00.000 0000 000.00 Completed Clinical Trials - General
7. Debt - General 01-Jun-2015 000.00 Completed Clinical Trials - General
6. Later Stage VC (Series C) 30-Jul-2014 0000 000.00 000.00 Completed Clinical Trials - General
5. Early Stage VC (Series B) 13-Nov-2012 0000 000.00 000.00 Completed Clinical Trials - General
4. Grant 01-Jan-2012 000000 00.000 Completed Product Development
3. Early Stage VC (Series A) 31-Mar-2011 $1.76M $4.26M 000.00 Completed Product Development
2. Grant 01-Jan-2010 $200K $2.5M Completed Startup

Epic Sciences Cap Table

To view Epic Sciences‘s complete cap table, request access »
Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series E 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series D 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series C1 00,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.000
Series B1 16,003,560 $0.000100 $0.04 $0.56 $0.56 1x $0.56 6.65%
Series A1 6,050,104 $0.000100 $0.02 $0.28 $0.28 1x $0.28 2.51%

Epic Sciences Competitors (39)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
Nucleix Venture Capital-Backed Rehovot, Israel 00 000.00 0000000000 000.00
00000000000 000000 Venture Capital-Backed Birmingham, AL 00 00.000 0000000000 0 00.000
000000000 00000000 Venture Capital-Backed Lausanne, Switzerland 00 000.00 00000000000 000.00
00000 Venture Capital-Backed Menlo Park, CA 000 00000000000 000
0000000000 Venture Capital-Backed Rehovot, Israel 00 000.00 00000000000 000.00

Epic Sciences Executive Team (19)

Name Title Board Seat Contact Info
Lloyd Sanders Chief Executive Officer, Board Member & President
Pascal Bamford Ph.D Chief Scientific Officer and Head of Laboratory Operations
Joel Smith JD Chief Financial Officer & General Counsel
Ryan Dittamore Chief of Medical Innovation and Head of Translational Research Partnerships
Dena Marrinucci Ph.D Co-Founder & Member Clinical Advisory Board

13 Former Executives

Epic Sciences Board Members (11)

To view Epic Sciences‘s full board member team, request access »
Name Representing Role Since
Andrew ElBardissi MD Deerfield Management Board Member 000 0000
Charles Kennedy MD Blue Ox Healthcare Partners Board Member 000 0000
Evgeny Zaytsev Ph.D RusnanoMedInvest Board Member 000 0000
Gary Gong Self Board Member 000 0000
Gregory Critchfield MD Self Board Member 000 0000

Epic Sciences Investors (20)

To view Epic Sciences‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Blue Ox Healthcare Partners Growth/Expansion Minority 000 0000 000000 0
Deerfield Management Venture Capital Minority 000 0000 000000 0
LabCorp Ventures Corporate Venture Capital Minority 000 0000 000000 0
Varian Other Minority 000 0000 000000 0
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0

Ready to get started?

Request a free trial